Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03604341 · ClinicalTrials.gov registry record · Phase 4

Cannabinoids for Pain Control During Medical Abortion

A Phase 4 study of Pain and Medical Abortion, sponsored by Oregon Health and Science University.

Completed
Registry status
Phase 4
Development phase
72
Enrollment target
1
Study location

NCT03604341 is a Phase 4 study of Pain and Medical Abortion that has completed, run by Oregon Health and Science University. The registered enrollment target is 72 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03604341, a Phase 4 study of Pain and Medical Abortion, has completed, sponsored by Oregon Health and Science University.

COMPLETED
Registry status
Phase 4
Development phase
72 participants
Enrollment target
1
Study location

Study Summary

The objective of this study is to determine if a synthetic cannabis derivative, dronabinol, in addition to ibuprofen, decreases maximum pain scores compared to ibuprofen and placebo in women undergoing medical abortion. Results of this study will help providers counsel patients regarding cannabis use during medical abortion.

Conditions Studied

Interventions

  • OTHER Placebo
  • DRUG Dronabinol 5mg Cap

Study Locations (1)

Oregon

  • Oregon Health & Science University - Portland

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2018-11-01
Est. Completion 2019-05-28
Phase Phase 4

What the Registry Record Tells You About NCT03604341

The ClinicalTrials.gov registry entry for NCT03604341 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (76% lower). The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03604341 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.

Frequently Asked Questions

What is clinical trial NCT03604341 about?

NCT03604341 is a clinical study titled "Cannabinoids for Pain Control During Medical Abortion". The objective of this study is to determine if a synthetic cannabis derivative, dronabinol, in addition to ibuprofen, decreases maximum pain scores compared to ibuprofen and placebo in women undergoing medical abortion. Results of this study will help providers counsel patients regarding cannabis us...

What is the current status of trial NCT03604341?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 72 participants. The study started on 2018-11-01. Estimated completion is 2019-05-28.

What conditions does trial NCT03604341 study?

This clinical trial studies the following conditions: Pain, Medical Abortion.

What interventions are being tested in trial NCT03604341?

The interventions under investigation include: Placebo (OTHER), Dronabinol 5mg Cap (DRUG).

Who is sponsoring clinical trial NCT03604341?

This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03604341 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.